
WALD Stock Forecast & Price Target
WALD Analyst Ratings
Bulls say
Waldencast is currently undergoing a strategic review in order to maximize shareholder value and bridge the perceived disconnect between its market value and brand assets. The company has recently sold off its Obagi Japan trademark rights and is focusing on developing and marketing new products, particularly in the Milk Makeup segment. However, risks such as reliance on third-party suppliers, potential dilution from new securities, and an ongoing SEC investigation could impact the company's future performance, along with a slowing beauty market and inflation in supply chain costs. Despite these risks, the company has a strong leadership team and is proactively addressing its challenges, indicating positive potential for future growth.
Bears say
Waldencast is facing several challenges in both its Obagi Skincare and Milk Makeup segments. Both segments experienced a decline in gross margin, with Obagi recording a significant 580bps decrease. This, in combination with lower-than-expected revenue and earnings results, suggests potential issues with the brand's pricing power and ability to drive demand. Adding to concerns is the fact that the company is still undergoing a strategic review and has not provided any guidance for the next fiscal year, leaving uncertainty regarding future performance.
This aggregate rating is based on analysts' research of Waldencast Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.
WALD Analyst Forecast & Price Prediction
Start investing in WALD
Order type
Buy in
Order amount
Est. shares
0 shares